Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 30

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 30
---
 the event of environmental discharge or contamination or an accident, we may be held liable for
any resulting damages, and any liability could exceed our resources. In addition, we may be subject to liability and may be required to
comply with new or existing environmental laws regulating pharmaceuticals or other medical products in the environment.

We are currently party to,
and may in the future, become subject to litigation or claims arising in or outside the ordinary course of business that could negatively
affect our business operations and financial condition.

We are currently party to, and may in the future, become subject
to litigation or claims arising in or outside the ordinary course of business (other than intellectual property infringement actions)
that could negatively affect our business operations and financial condition, including securities class actions which are typically expensive
to defend. Such claims and litigation proceedings may be brought by third parties, including our competitors, advisors, service providers,
partners or collaborators, employees, and governmental or regulatory bodies. For information on legal proceedings, please see “ Item
8. Financial Information - A. Financial Statements and Other Financial Information - Legal Proceedings.” Any claims
and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management attention
and resources, and lead to attempts on the part of other parties to pursue similar claims. We may not be able to determine the amount
of any potential losses and other costs we may incur due to the inherent uncertainties of litigation and settlement negotiations. In the
event we are required or decide to pay amounts in connection with any claims or lawsuits, such amounts could be significant and could
have a material adverse impact on our liquidity, business, financial condition and results of operations. In addition, depending on the
nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results, our cash flows
or both. Additionally, we may be unable to maintain our existing directors’ and officers’ liability insurance in the future
at satisfactory rates or adequate coverage amounts and may incur significant increases in insurance costs.

Risks Related to Intellectual Property

Our access to most of the
intellectual property associated with our therapeutic candidates results from in-license agreements with biotechnology companies, the
termination of which would prevent us from commercializing the associated therapeutic candidates.

We do not conduct our own initial research with respect to the
identification of our therapeutic candidates. Instead, we rely upon research and development work conducted by third parties as the primary
source of our therapeutic candidates. As such